Stephan Ogenstad

692 total citations
35 papers, 550 citations indexed

About

Stephan Ogenstad is a scholar working on Oncology, Genetics and Psychiatry and Mental health. According to data from OpenAlex, Stephan Ogenstad has authored 35 papers receiving a total of 550 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Genetics and 6 papers in Psychiatry and Mental health. Recurrent topics in Stephan Ogenstad's work include Blood disorders and treatments (11 papers), Neutropenia and Cancer Infections (10 papers) and Cancer Treatment and Pharmacology (8 papers). Stephan Ogenstad is often cited by papers focused on Blood disorders and treatments (11 papers), Neutropenia and Cancer Infections (10 papers) and Cancer Treatment and Pharmacology (8 papers). Stephan Ogenstad collaborates with scholars based in United States, Sweden and China. Stephan Ogenstad's co-authors include Jan Sjövall, Finn Reiestad, Magnus Björkholm, C. Wedelin, G. Holm, Anders Karlsson, Eric Sandström, Edward Baral, Arne Wallgren and Ramon Mohanlal and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Stephan Ogenstad

33 papers receiving 522 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephan Ogenstad United States 15 102 101 86 86 66 35 550
Denise Lowe United States 14 54 0.5× 134 1.3× 59 0.7× 24 0.3× 62 0.9× 26 485
Satoshi Egawa Japan 14 136 1.3× 81 0.8× 200 2.3× 22 0.3× 110 1.7× 53 714
Aaron Grossman United States 14 90 0.9× 95 0.9× 100 1.2× 42 0.5× 21 0.3× 23 588
Yuyang Zhang China 11 69 0.7× 44 0.4× 85 1.0× 23 0.3× 41 0.6× 34 424
Kate E. Therkelsen United States 12 154 1.5× 109 1.1× 90 1.0× 37 0.4× 99 1.5× 24 879
Thomas Wiesel Germany 12 96 0.9× 47 0.5× 84 1.0× 14 0.2× 43 0.7× 17 477
Rebecca Wang United States 11 103 1.0× 89 0.9× 50 0.6× 38 0.4× 45 0.7× 30 887
Ning An China 17 108 1.1× 40 0.4× 57 0.7× 88 1.0× 187 2.8× 67 792
Keyvan Ghadimi Iran 10 45 0.4× 26 0.3× 53 0.6× 85 1.0× 26 0.4× 38 332
Keith Byron Australia 15 47 0.5× 127 1.3× 53 0.6× 95 1.1× 95 1.4× 32 786

Countries citing papers authored by Stephan Ogenstad

Since Specialization
Citations

This map shows the geographic impact of Stephan Ogenstad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Ogenstad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Ogenstad more than expected).

Fields of papers citing papers by Stephan Ogenstad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Ogenstad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Ogenstad. The network helps show where Stephan Ogenstad may publish in the future.

Co-authorship network of co-authors of Stephan Ogenstad

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Ogenstad. A scholar is included among the top collaborators of Stephan Ogenstad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Ogenstad. Stephan Ogenstad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Feinstein, Trevor, Stephan Ogenstad, Dominic Mitchell, Lan Huang, & Ramon Mohanlal. (2022). DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires.. Journal of Clinical Oncology. 40(16_suppl). 9091–9091. 3 indexed citations
2.
Mohanlal, Ramon, Stephan Ogenstad, Lynn L. H. Huang, & Douglas W. Blayney. (2021). 1708P Severe neutropenia (grade 4, Gr4N) as a population-based predictor for adverse clinical outcome of chemotherapy induced neutropenia (CIN). Annals of Oncology. 32. S1189–S1190. 1 indexed citations
3.
4.
Blayney, Douglas W., Yuankai Shi, Igor Bondarenko, et al.. (2021). Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1.. Journal of Clinical Oncology. 39(15_suppl). 547–547. 2 indexed citations
5.
6.
Blayney, Douglas W., Stephan Ogenstad, Yuankai Shi, et al.. (2018). P1.01-06 Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients. Journal of Thoracic Oncology. 13(10). S461–S461. 2 indexed citations
7.
McFarlin, Brian K., Adam S. Venable, Katie C Carpenter, Andrea L. Henning, & Stephan Ogenstad. (2017). Oral Supplementation with Baker's Yeast Beta Glucan Is Associated with Altered Monocytes, T Cells and Cytokines following a Bout of Strenuous Exercise. Frontiers in Physiology. 8. 786–786. 19 indexed citations
8.
Ogenstad, Stephan. (1998). The use of generalized tests in medical research. Journal of Biopharmaceutical Statistics. 8(4). 497–508. 8 indexed citations
9.
Wiemann, B, Dimitry M. Danilenko, Yan Qiao, et al.. (1998). Combined Treatment of Acute EAE in Lewis Rats with TNF-Binding Protein and Interleukin-1 Receptor Antagonist. Experimental Neurology. 149(2). 455–463. 26 indexed citations
10.
11.
Yisak, W., et al.. (1993). Interaction study between remoxipride and biperiden. Psychopharmacology. 111(1). 27–32. 5 indexed citations
12.
Lewander, Tommy, et al.. (1992). Remoxipride and haloperidol in the treatment of acute phase schizophrenia. Schizophrenia Research. 6(2). 110–110. 1 indexed citations
13.
Bahr, Christer von, et al.. (1991). Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. Psychopharmacology. 103(4). 443–448. 33 indexed citations
14.
Yisak, W., C von Bahr, Lars Farde, et al.. (1990). Drug interaction studies with remoxipride. Acta Psychiatrica Scandinavica. 82(S358). 58–62. 3 indexed citations
15.
Reiestad, Finn, et al.. (1988). Intrapleural Administration of 0.25%, 0.375%, and 0.5% Bupivacaine with Epinephrine after Cholecystectomy. Anesthesia & Analgesia. 67(5). 430???434–430???434. 66 indexed citations
16.
Farde, Lars, Margaretha Grind, Michael Nilsson, Stephan Ogenstad, & Göran Sedvall. (1988). Remoxipride ? a new potential antipsychotic drug. Psychopharmacology. 95(2). 157–61. 22 indexed citations
17.
Sjövall, Jan, et al.. (1988). Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clinical Pharmacology & Therapeutics. 44(1). 65–73. 57 indexed citations
18.
Wedelin, C., Magnus Björkholm, G. Holm, Stephan Ogenstad, & Håkan Mellstedt. (1982). Blood T‐Lymphocyte Functions in Healthy Adults in Relation to Age. Scandinavian Journal of Haematology. 28(1). 45–53. 25 indexed citations
19.
Baral, Edward, Henric Blomgren, Arne Wallgren, et al.. (1979). Prognostic Relevance of Radiation Induced Immune Suppression in Breast Carcinoma. PubMed. 18(4). 313–320. 6 indexed citations
20.
Baral, Edward, Henric Blomgren, B Petrini, et al.. (1977). Prognostic Relevance of Immunologic Variables in Breast Carcinoma. Acta Radiologica Therapy Physics Biology. 16(5). 417–426. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Denise Lowe Breakdown of academic impact, for papers by Satoshi Egawa Breakdown of academic impact, for papers by Aaron Grossman Breakdown of academic impact, for papers by Yuyang Zhang Breakdown of academic impact, for papers by Kate E. Therkelsen Breakdown of academic impact, for papers by Thomas Wiesel Breakdown of academic impact, for papers by Rebecca Wang Breakdown of academic impact, for papers by Ning An Breakdown of academic impact, for papers by Keyvan Ghadimi Breakdown of academic impact, for papers by Keith Byron
Rankless by CCL
2026